Quest Diagnostics Stock Issuance Proceeds increased by 261.1% to $65.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 124.1%, from $29.00M to $65.00M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -11.5% CAGR.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $51.00M | $40.00M | $21.00M | $10.00M | $58.00M | $28.00M | $27.00M | $25.00M | $22.00M | $13.00M | $12.00M | $12.00M | $16.00M | $24.00M | $21.00M | $29.00M | $13.00M | $19.00M | $18.00M | $65.00M |
| QoQ Change | — | -21.6% | -47.5% | -52.4% | +480.0% | -51.7% | -3.6% | -7.4% | -12.0% | -40.9% | -7.7% | +0.0% | +33.3% | +50.0% | -12.5% | +38.1% | -55.2% | +46.2% | -5.3% | +261.1% |
| YoY Change | — | — | — | — | +13.7% | -30.0% | +28.6% | +150.0% | -62.1% | -53.6% | -55.6% | -52.0% | -27.3% | +84.6% | +75.0% | +141.7% | -18.8% | -20.8% | -14.3% | +124.1% |